Last reviewed · How we verify
NCT03118544: REDUCe
REduction of Contrast Via DyeVert Used in CTO Procedures
trial testing DyeVert System in Chronic Total Occlusion of Coronary Artery in 21 participants. Terminated before completion.
2 February 2018
Quick facts
| Lead sponsor | Minneapolis Heart Institute Foundation |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 21 |
| Start date | 26 March 2017 |
| Primary completion | 2 February 2018 |
| Estimated completion | 2 February 2018 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- DyeVert System
Conditions studied
- Chronic Total Occlusion of Coronary Artery — all drugs for Chronic Total Occlusion of Coronary Artery →
Sponsor
Minneapolis Heart Institute Foundation
Who can join
18 and older, any sex, with Chronic Total Occlusion of Coronary Artery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The is an observational, prospective study to evaluate the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated chronic total occlusion (CTO) percutaneous coronary intervention (PCI)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03118544
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Total Occlusion of Coronary Artery
Currently open trials in the same condition.
- NCT06414551 — Calcification on CTCA of a CTO and PCI Outcomes · recruiting
- NCT06193954 — VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions · NA · recruiting
- NCT03756870 — Revascularization Versus Optimal Medical Therapy of Chronic Total Coronary Occlusions on Left Ventricular Ischemia Reduc · NA · recruiting
- NCT03563417 — ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO · NA · recruiting
- NCT03392415 — The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion · NA · active not recruiting
Other Minneapolis Heart Institute Foundation trials
Trials by the same sponsor.
- NCT06804980 — DESIFOR-EXPAND (MHIF) · Phase 4 · recruiting
- NCT04763460 — Effects of CRT Optimization as Assessed by Cardiac MR · NA · withdrawn
- NCT05440084 — Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity · terminated
- NCT05065073 — Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography · Phase 4 · unknown
- NCT05100940 — Progress Complication · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03118544 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Minneapolis Heart Institute Foundation
- Last refreshed: 17 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03118544.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing